Aeonian Pharmaceuticals secures funding to develop mTORC1 inhibitors
In connection with the investment, James Peyer, Managing Partner of Apollo Ventures, has joined Aeonian's Board of Directors. Aeonian is an early-stage company engaged in the discovery and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.